The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations

Isabel Soria‐Bretones, Kelsie L. Thu, Jennifer Silvester, Jennifer Cruickshank, Samah El Ghamrasni, Wail Ba-Alawi, Graham C. Fletcher, Reza Kiarash, Mitchell J. Elliott, Jordan J. Chalmers, Andrea C. Elia, Albert Cheng, April A. N. Rose, Mark R. Bray, Benjamin Haibe-Kains, Tak W. Mak, David W. CesconScience 2022 · DOI · OpenAlex

Abstract

This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients. <strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer cell lines (T47D, LY2, MDA-MB-361, CAMA1, MCF7, KPL1, ZR751, HCC1428) both at the untreated or Parental state and post resistance to Palbociclib.</strong> Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (6-8 months for cell lines). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R cell lines were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.
BibTeX
@inproceedings{soriabretones2022spindle,
  author = {Isabel Soria‐Bretones and Kelsie L. Thu and Jennifer Silvester and Jennifer Cruickshank and Samah El Ghamrasni and Wail Ba-Alawi and Graham C. Fletcher and Reza Kiarash and Mitchell J. Elliott and Jordan J. Chalmers and Andrea C. Elia and Albert Cheng and April A. N. Rose and Mark R. Bray and Benjamin Haibe-Kains and Tak W. Mak and David W. Cescon},
  title = {{The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations}},
  booktitle = {Science},
  year = {2022},
  doi = {10.5281/zenodo.6760819},
}

Loading related content...

Figure